This should be the standard of posting on this board, not the...

First 3352 Last

Share
Profile

Follow
Jakolu

141 Posts.

42

06/11/23

18:56

Post #: 70754753
Share

Originally posted by dalts66: ↑

As it is for a paediatric disease with no SOC and little survival rate, I too think they will get the FDA nod. Adverse events have been reduced so safety is ok.

Not meeting the endpoints might Sway some medical professionals from wanting to use it, but parents will be desperate and willing to give it a try.

All of this will be in play when ANP take their results to the FDA/EMA. Remembering to try that 1102 targets inflammation, so a different mode of treatment for the disease, and with data showing previous treatment by exxon skipping drugs doesn't stop it from working, ANP should have a pretty good shot at goal.

Those same parents will still be interested, even after using a gene therapy, as they want every chance for their child. Roll out into ambulant boys should not be too much of a hurdle.

We are really looking at nearly 100% of DMD patients here. If we can show enough evidence. Sarepta have shown how the FDA look at approving drugs. ANP should be feeling pretty confident.

Look at the market cap ! its crazy low.

Last dosing of the tox study imminent. ATL 1102 is hitting arms. 8 or so months until we start seeing data. We have waited this long, but now there is a tiny light starting to shone on the horizon.

Expand

This should be the standard of posting on this board, not the constant bickering and name calling! Thanks for the post Dalts

ANP Price at posting: 5.7¢ Sentiment: Buy Disclosure: Held
9 Upvote

0 Great analysis

Reply

Top Stories

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Has uranium run out of steam? An update on nuclear markets & developments ahead in FY25

SS1

Sun Silver to kick off drilling next week at 292Moz Maverick Springs silver-gold project

World Gold Council says market in want of catalyst; flags Asia sell-off risks. Then there's Trump

AHK

Ark Mines inks 1.5Bt Exploration Target for Sandy Mitchell REE play including NdPr; PFS due in Q4

There are more pages in this discussion • 175 more messages in this thread...

First 3352 Last

Add PER (ASX) to my watchlist

(20min delay)
Last 8.4¢		Change 0.004(5.00%)		Mkt cap ! $75.72M

Open	High	Low	Value	Volume
8.0¢	8.4¢	8.0¢	$26.89K	328.0K

Buyers (Bids)

No.	Vol.	Price($)
1	9602	8.3¢

Sellers (Offers)

Price($)	Vol.	No.
8.4¢	58051	1

View Market Depth

No.	Vol.	Price($)
1	9602	0.083
1	5500	0.082
1	75000	0.081
2	85000	0.080
2	27150	0.079

Price($)	Vol.	No.
0.084	58051	1
0.085	106431	2
0.086	100000	1
0.087	125000	1
0.089	135000	2

Last trade - 16.10pm 03/07/2024 (20 minute delay)

PER (ASX) Chart

This should be the standard of posting on this board, not the...

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Has uranium run out of steam? An update on nuclear markets & developments ahead in FY25

Sun Silver to kick off drilling next week at 292Moz Maverick Springs silver-gold project

World Gold Council says market in want of catalyst; flags Asia sell-off risks. Then there's Trump

Ark Mines inks 1.5Bt Exploration Target for Sandy Mitchell REE play including NdPr; PFS due in Q4

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

This should be the standard of posting on this board, not the...

Top Stories

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Has uranium run out of steam? An update on nuclear markets & developments ahead in FY25

Sun Silver to kick off drilling next week at 292Moz Maverick Springs silver-gold project

World Gold Council says market in want of catalyst; flags Asia sell-off risks. Then there's Trump

Ark Mines inks 1.5Bt Exploration Target for Sandy Mitchell REE play including NdPr; PFS due in Q4

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News